Literature DB >> 23255880

The interpretation of clinical studies on the photodynamic treatment of actinic keratosis.

Debra K Kelleher1, Helmut Piazena.   

Abstract

Actinic keratosis is one of the most commonly treated skin conditions. A number of studies have recently been published on the treatment of this ailment using photodynamic therapy. The authors of this letter are concerned about the interpretation of some of these studies and would like to outline possible misinterpretations which may arise due to an incomplete analysis of the study reports available. Clearly, the "ideal" therapy for actinic keratosis should be a carefully chosen compromise between undesired side-effects and therapeutic efficacy and needs to be based on a consideration of all of the relevant clinical studies.

Entities:  

Keywords:  5-aminolaevulinic acid; actinic keratosis; dermatology; light sources; methyl-5-aminolaevulinate; photodynamic therapy

Mesh:

Substances:

Year:  2012        PMID: 23255880      PMCID: PMC3525885          DOI: 10.3205/000168

Source DB:  PubMed          Journal:  Ger Med Sci        ISSN: 1612-3174


Letter

In the outpatient setting, actinic keratosis is one of the most commonly treated skin conditions, the prevalence of which increases with cumulative skin exposure and increasing age. Rates of 11–25% have been reported in the northern hemisphere and of 40–60% in Australia [1]. Actinic keratoses are strong predictors of squamous cell carcinomas and are believed to be precursors of squamous cell carcinomas of the skin [1]. This condition therefore presents a growing public health problem. A number of studies have been published recently concerning modalities of photodynamic therapy (PDT) treatment for actinic keratosis in which the efficacy of several photosensitisers and/or light sources were compared [2], [3], [4], [5]. The most recent of these is the study by Dirschka and colleagues [5] which appeared recently in the British Journal of Dermatology and in which a gel formulation of 5-aminolaevulinic acid (BF-200 ALA) was found to be superior to methyl-5-aminolaevulinate (MAL). In the same study, the narrow-band light sources were found to be more effective than the broad-band light sources, although the narrow-band sources were associated with a higher occurrence and severity of adverse effects, which included pain, burning, erythema and exfoliation, irrespective of the photosensitizer used. While such a multicenter, randomized study is to be commended, the authors – in our opinion – failed to appropriately consider their findings in the light of previous studies, since a number of pertinent and highly relevant articles were not mentioned. An important study in this context is the study by von Felbert and colleagues [2] with a longer follow-up time of 12 months (compared to 12 weeks in the study of Dirschka et al. [5]) and in which the use of narrow-band and broad-band sources were found to be equally effective. One reason given by von Felbert and colleagues [2] for the comparable efficiency of these sources was the use of a more advanced and efficient broad-band optical filter (in comparison to the broad-band sources used in previous studies). Dirschka et al. [5] however, not only failed to discuss reasons for the differences between the narrow-band and broad-band types of sources used, but also did not comment on the differences found between the various types of broad-band sources employed. Additionally, despite the findings of von Felbert et al. [2] who found the use of a broad-band source with water filter to be associated with less pain than that caused by a narrow-band source, and a study by Apalla et al. [6] who found the use of a broad-band source without a water filter to be associated with pain, Dirschka and colleagues did not consider the fact that broad-band sources would result in absorption over a broader spectral range (and possibly encompassing several maxima) of the photosensitizer as has been discussed previously [7]. Additionally, previous studies in which no differences were found between narrow- and broad-band sources [1], [8], [9] were not considered. Their study also demonstrated that the conditions under which PDT was applied had a pronounced impact on the efficiency of the treatment. For MAL, the von Felbert study [1] also found considerably higher response rates (80% total clearance) as compared to the Dirschka et al. [5] study in which a clearance rate of 64.2% was obtained. Possible reasons for such a pronounced difference between the response rates in these two studies were however not discussed by Dirschka and colleagues [5]. While the extent of pain experienced during photodynamic therapy (which is deemed to be the main side-effect of PDT [6], [7]) was documented by Dirschka et al. [5], possible reasons for the greater incidence of pain during the use of the narrow-band sources were not considered. In the Dirschka et al. study, a comparison of the photosensitizers used showed BF-200 ALA to be superior to MAL, but again, a study with contradictory findings (Gholam et al. [3]) is not discussed. While we do not wish to infer that the study performed by Dirschka and colleagues is in any way erroneous, we would nevertheless like to point out that the discussion of the results and the authors’ selection of cited literature appears to be biased towards studies supporting the authors’ own findings. The problem of such a bias has recently been outlined [10], together with the need for an up-to-date selection of literature and the recommendation that a concealment of contradictory or critical literature should be avoided. As a result of the rather selective choice of literature provided and the lack of a thorough consideration of the relevant studies already published, the article by Dirschka and colleagues [5] leaves a number of questions unanswered. Furthermore, the corresponding editorial published in the same issue of the British Journal of Dermatology [11] is unfortunately also based on the acceptance of the “superiority” of BF-200 ALA in comparison to MAL as well as the “superiority” of narrow-band in comparison to broad-band sources and fails to address the fact that several other studies have found contradictory results. Certainly, sweeping statements claiming e.g., narrow-band sources to be preferable to broad-band sources or BF-200 to be better than MAL should not be made on the basis of a single study, especially since such statements may lead to rapid and ungrounded propagation of therapeutic protocols. In conclusion, it would appear that the last word concerning the optimal photosensitizer and radiation source for the treatment of actinic keratosis has not yet been spoken. Obviously, the “ideal” therapy for actinic keratosis should be a carefully chosen compromise between undesired side-effects and therapeutic efficacy and needs to be based on a consideration of all of the relevant clinical studies.

Notes

Competing interests

The authors declare that they have no competing interests.
  11 in total

1.  Photodynamic therapy for actinic keratoses: procedure matters?

Authors:  A Hauschild
Journal:  Br J Dermatol       Date:  2012-01       Impact factor: 9.302

2.  Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis.

Authors:  Patrick Gholam; Tanja Weberschock; Katharina Denk; Alexander Enk
Journal:  Dermatology       Date:  2011-07-12       Impact factor: 5.366

3.  The virtues of correct citation: careful referencing is important but is often neglected/even in peer reviewed articles.

Authors:  Stephan Mertens; Christopher Baethge
Journal:  Dtsch Arztebl Int       Date:  2011-08-19       Impact factor: 5.594

Review 4.  Epidemiology of solar keratoses.

Authors:  C A Frost; A C Green
Journal:  Br J Dermatol       Date:  1994-10       Impact factor: 9.302

5.  Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo.

Authors:  T Dirschka; P Radny; R Dominicus; H Mensing; H Brüning; L Jenne; L Karl; M Sebastian; C Oster-Schmidt; W Klövekorn; U Reinhold; M Tanner; D Gröne; M Deichmann; M Simon; F Hübinger; G Hofbauer; G Krähn-Senftleben; F Borrosch; K Reich; C Berking; P Wolf; P Lehmann; M Moers-Carpi; H Hönigsmann; K Wernicke-Panten; C Helwig; M Foguet; B Schmitz; H Lübbert; R-M Szeimies
Journal:  Br J Dermatol       Date:  2011-12-21       Impact factor: 9.302

6.  Photodynamic therapy of multiple actinic keratoses: reduced pain through use of visible light plus water-filtered infrared A compared with light from light-emitting diodes.

Authors:  V von Felbert; G Hoffmann; S Hoff-Lesch; F Abuzahra; C N Renn; L R Braathen; H F Merk
Journal:  Br J Dermatol       Date:  2010-09       Impact factor: 9.302

Review 7.  Photodynamic therapy and the role of heat shock protein 70.

Authors:  Doris Helbig; Jan C Simon; Uwe Paasch
Journal:  Int J Hyperthermia       Date:  2011-10-03       Impact factor: 3.914

8.  Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study.

Authors:  R-M Szeimies; P Radny; M Sebastian; F Borrosch; T Dirschka; G Krähn-Senftleben; K Reich; G Pabst; D Voss; M Foguet; R Gahlmann; H Lübbert; U Reinhold
Journal:  Br J Dermatol       Date:  2010-05-28       Impact factor: 9.302

9.  Split-face-study using two different light sources for topical PDT of actinic keratoses:non-inferiority of the LED system.

Authors:  Philipp Babilas; Richard Travnik; Annegret Werner; Michael Landthaler; Rolf-Markus Szeimies
Journal:  J Dtsch Dermatol Ges       Date:  2007-11-09       Impact factor: 5.584

10.  In vitro and in vivo comparison of two different light sources for topical photodynamic therapy.

Authors:  P Babilas; E Kohl; T Maisch; H Bäcker; B Gross; A L Branzan; W Bäumler; M Landthaler; S Karrer; R-M Szeimies
Journal:  Br J Dermatol       Date:  2006-04       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.